Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in adaptive designs for Phase I/II dose-finding studies.

Sarah Zohar1, Sylvie Chevret

  • 1Inserm U717, Département de Biostatistique et Informatique Médicale, Hôpital Saint-Louis, Paris, France.

Journal of Biopharmaceutical Statistics
|November 21, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Innovative Clinical Trial Approach for Evaluating Digital Medical Devices Under European Fast-Track Regulatory Frameworks.

Statistics in medicine·2026
Same author

In Silico Clinical Trials in Drug Development: A Systematic Review.

Therapeutic innovation & regulatory science·2025
Same author

Digital pharmacological twins: Bridging multi-scale modelling and artificial intelligence for precision medicine: The DIGPHAT consortium.

Therapie·2025
Same author

Modeling Whole-Body Dynamic PET Microdosing Data to Predict the Whole-Body Pharmacokinetics of Glyburide in Humans.

Clinical pharmacokinetics·2025
Same author

The ED<sub>95</sub> of lidocaine and prilocaine for ultrasound-guided brachial plexus blocks for surgical anaesthesia: a randomised controlled clinical trial.

BJA open·2025
Same author

An efficient joint model for high dimensional longitudinal and survival data via generic association features.

Biometrics·2024
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Cancer dose-finding trials are evolving. This study presents three new methods to find the optimal dose, balancing efficacy and safety in early-phase clinical trials.

Area of Science:

  • Oncology
  • Clinical Trial Design
  • Biostatistics

Background:

  • Traditional cancer dose-finding trials focus on the maximum tolerated dose (MTD).
  • Ethical constraints necessitate adaptive designs for sequential patient allocation based on responses.
  • The MTD concept is expanding to include optimal efficacy under toxicity constraints.

Purpose of the Study:

  • To introduce three novel approaches for estimating the optimal dose in Phase I/II cancer trials.
  • To extend the concept of dose-finding beyond MTD to include efficacy-based dose selection.
  • To provide practical illustrations of these methods through case studies.

Main Methods:

  • Review and presentation of three distinct methodologies for dose-finding.
  • Application of adaptive trial designs incorporating efficacy and toxicity criteria.

Related Experiment Videos

  • Utilizing case studies to demonstrate the practical implementation of the proposed approaches.

    • Main Results:

    • The paper outlines three distinct strategies for determining an optimal dose in early-phase cancer studies.
    • These methods integrate both treatment efficacy and safety profiles.
    • Case studies illustrate the application and potential benefits of these advanced dose-finding techniques.

    Conclusions:

    • New approaches offer a more comprehensive way to define optimal cancer treatment doses.
    • These methods enhance dose selection by considering both efficacy and toxicity.
    • The presented strategies are valuable for designing effective Phase I/II cancer trials.